FDA Grants Fast Track Designation to MC001 for Pancreatic Cancer

Medicovestor has announced that the FDA has granted Fast Track designation to MC001, its first-in-class chemoimmunotherapy antibody-drug conjugate (ADC), for the treatment of pancreatic cancer. This designation aims to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.